Povidone-iodine used as an adjunct to non-surgical treatment of furcation involvements.
Povidone-iodine used as an adjunct to non-surgical treatment of furcation involvements.
复制标题
聚维酮碘用作分叉受累非手术治疗的辅助药物。
DOI：
--
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
M. Casati
中科院分区：
文献类型：
--
作者：
Érica Del Peloso Ribeiro;S. Bittencourt;G. Ambrosano;F. Nociti;E. Sallum;A. Sallum;M. Casati
背景
该临床试验的目的是评估局部应用聚维酮碘（聚乙烯吡咯烷酮和碘 [PVP-I]）作为分叉受累非手术治疗的辅助疗法的效果。
方法
招募了 44 名至少有 1 处 II 级分叉受累的患者，这些患者在探诊深度 (PD)> 或 = 5 mm 的探诊时出血。将患者分为两个治疗组：1) 使用 PVP-I (10%) 作为冷却液，通过超声装置进行龈下器械治疗（测试）； 2)使用蒸馏水作为冷却液进行相同的处理(对照)。评估以下临床结果：菌斑指数、探诊出血（BOP）、龈缘位置、相对附着水平（RAL）、PD和相对水平附着水平（RHAL）。 N-苯甲酰-L-精氨酸-对硝基苯胺（BAPNA）测试用于分析牙齿生物膜中的胰蛋白酶样活性。在基线以及治疗后1、3和6个月时评估临床和生化参数。
结果
两组的 PD 减少以及 RAL 和 RHAL 增益均相似。 6 个月时，对照组的这些变量分别为 2.31、1.17 和 1.00 毫米，测试组的这些变量分别为 2.31、1.23 和 1.02 毫米。关于呈现 RAL 增益 > 或 = 2 mm 的分叉位点数量，各组之间也没有差异。 BAPNA 测试的结果未能证明组间存在显着差异。
结论
非手术治疗可以有效治疗 II 类分叉受累，并且使用局部应用的 PVP-I 作为龈下器械的辅助手段并不能提供额外的益处。
BACKGROUND
The aim of this clinical trial was to evaluate the effect of topically applied povidone-iodine (polyvinylpyrrolidone and iodine [PVP-I]) used as an adjunct to non-surgical therapy of furcation involvements.
METHODS
Forty-four patients presenting at least one Class II furcation involvement that bled on probing with probing depth (PD)>or=5 mm were recruited. Patients were stratified into two treatment groups: 1) subgingival instrumentation by an ultrasonic device using PVP-I (10%) as the cooling liquid (test); and 2) identical treatment using distilled water as the cooling liquid (control). The following clinical outcomes were evaluated: plaque index, bleeding on probing (BOP), position of the gingival margin, relative attachment level (RAL), PD, and relative horizontal attachment level (RHAL). The N-benzoyl-L-arginine-p-nitroanilide (BAPNA) test was used to analyze the trypsin-like activity in dental biofilm. The clinical and biochemical parameters were evaluated at baseline and 1, 3, and 6 months after therapy.
RESULTS
Both groups had similar means of PD reduction and RAL and RHAL gain. At 6 months, these variables were, respectively, 2.31, 1.17, and 1.00 mm in the control group and 2.31, 1.23, and 1.02 mm in the test group. There was also no difference between groups regarding the number of furcation sites presenting RAL gain>or=2 mm. The results of the BAPNA test failed to demonstrate significant differences between groups.
CONCLUSION
Non-surgical therapy can effectively treat Class II furcation involvements, and the use of topically applied PVP-I as an adjunct to subgingival instrumentation does not provide additional benefits.